This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| docetaxel | |
|---|---|
| Name | Docetaxel |
| Tradenames | Taxotere, Docefez, others |
| Routes of administration | Intravenous |
| Class | Antineoplastic agent; taxane |
| Legal status | Prescription only |
| Bioavailability | 100% (IV) |
| Metabolism | Hepatic (CYP3A4) |
| Elimination half-life | 11 hours (mean) |
| Excretion | Fecal and renal |
docetaxel
Docetaxel is a semisynthetic taxane antineoplastic agent used to treat multiple solid tumors. It is administered intravenously in oncology practice and is indicated for conditions such as breast cancer, non-small-cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancers. The drug was developed from natural taxanes found in yew species and has played a major role in modern chemotherapy regimens.
Docetaxel is approved for treatment of metastatic and locally advanced breast cancer, often combined with agents used in adjuvant and neoadjuvant protocols alongside regimens associated with trials at MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Dana-Farber Cancer Institute. It is a standard option for non-small-cell lung cancer in regimens influenced by guidelines from the National Comprehensive Cancer Network and trials conducted at institutions such as Johns Hopkins Hospital and Mayo Clinic. In metastatic prostate cancer it is used with androgen-deprivation strategies informed by findings published from researchers at Harvard Medical School and University of Oxford. Gastric and head and neck indications derive from multicenter studies involving hospitals like Cleveland Clinic and Massachusetts General Hospital. Off-label and experimental uses have appeared in studies at Stanford University and University of California, San Francisco.
Docetaxel functions as a microtubule-stabilizing agent that promotes polymerization and inhibits depolymerization of tubulin heterodimers, interfering with mitotic spindle dynamics observed in cell biology work from laboratories at Cambridge University and University of California, Berkeley. This mechanism triggers mitotic arrest and apoptosis via pathways studied by groups at Max Planck Institute and Salk Institute. Interactions with signaling networks and resistance mechanisms have been characterized in research from Cold Spring Harbor Laboratory, Institut Pasteur, and Karolinska Institutet.
Docetaxel displays triphasic pharmacokinetics with hepatic biotransformation primarily through CYP3A4 enzymes characterized in pharmacology studies at University College London and University of Toronto. Elimination involves biliary excretion measured in trials at Vanderbilt University Medical Center and renal routes evaluated at UCSF Medical Center. Drug–drug interactions with agents such as inhibitors and inducers described by researchers at Imperial College London and McGill University are clinically significant, prompting monitoring when coadministered with drugs evaluated in registries at Karolinska University Hospital.
Typical dosing is weight- or surface-area–based and administered as an intravenous infusion in cycles defined by cooperative groups like European Organisation for Research and Treatment of Cancer and North Central Cancer Treatment Group. Regimens vary: single-agent schedules used in studies at Royal Marsden Hospital and combination regimens developed at Memorial Sloan Kettering Cancer Center specify dosing intervals, premedication with corticosteroids following protocols from Mayo Clinic and infusion durations standardized by guidance from American Society of Clinical Oncology and European Society for Medical Oncology.
Common adverse effects include neutropenia, febrile neutropenia, anemia, peripheral neuropathy, fluid retention, and mucositis reported in pivotal trials from EORTC, SWOG, and CALGB. Hepatotoxicity and hypersensitivity reactions resembling patterns documented in pharmacovigilance reports from FDA and EMA require management strategies used in centers such as Guy's Hospital and Royal Free Hospital. Long-term toxicities and quality-of-life outcomes were evaluated in survivorship studies at St Jude Children's Research Hospital and University of Pennsylvania.
Docetaxel is contraindicated in patients with severe hypersensitivity to formulation components and in those with severe neutropenia or marked hepatic impairment, recommendations aligned with labeling from agencies including European Medicines Agency and U.S. Food and Drug Administration. Caution is advised in patients with comorbidities managed at centers like Mount Sinai Hospital and Brigham and Women's Hospital. Dose adjustments are informed by laboratory monitoring protocols developed at Karolinska University Hospital and Guy's and St Thomas' NHS Foundation Trust.
Docetaxel is a semisynthetic analog derived from 10-deacetylbaccatin III, originally isolated from Taxus baccata and further developed in chemistry programs at Institut National des Sciences Appliquées and École Polytechnique. Formulations include polysorbate 80 vehicles and albumin-bound preparations inspired by nanoparticle research from MIT and Harvard University. Analytical characterization uses methods standardized by laboratories at National Institutes of Health and European Pharmacopoeia.
The development of docetaxel traces to natural product research on taxanes at CNRS and Institut Pasteur and industrial development by pharmaceutical companies with clinical programs run in collaboration with research hospitals such as Hôpital Saint-Louis and CHU de Nantes. Major clinical development involved multinational trials coordinated by groups including EORTC and SWOG, leading to regulatory approvals following submissions to FDA and EMA. Docetaxel's introduction reshaped chemotherapy practice alongside contemporaneous agents evaluated at institutions like Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center.
Category:Antineoplastic drugs